ASCO 2026: Corcept Therapeutics' CEO Joe Belanoff discusses cortisol modulation as an approach to cancer treatment, and the recent approval of Lifyorli for ovarian cancer

1 hour ago
1 min read

He describes the science behind cortisol and how Corcept chose ovarian cancer as its first indication because it highly expresses the glucocorticoid receptor. Plus, other cancers this approach might be useful for, and the rationale behind an NDA refiling for Cushing's syndrome.

Recent Posts

See All

ASCO 2026: Gilead CMO Dietmar Berger discusses the company's cell therapy and antibody-drug conjugate approaches in oncology, and shares the rationale on four recent acquisitions

Bay Area based Ridge Bio is using machine learning in the wet lab at large scale, but with a cell free platform, to develop optimized linkers for antibody-drug conjugates and precision enzymes

Ahead of ASCO, Corbus is providing updated data today on its Nectin-4 ADC in cervical and head and neck cancer - and has seen that response rate appears to be directly related to HPV status

ASCO 2026: Corcept Therapeutics' CEO Joe Belanoff discusses cortisol modulation as an approach to cancer treatment, and the recent approval of Lifyorli for ovarian cancer

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight